Pulmonary Drug Delivery Technologies: Market Research Report

Date: April 22, 2010
Pages: 599
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PB38A8B0A23EN
Leaflet:

Download PDF Leaflet

Pulmonary Drug Delivery Technologies: Market Research Report
This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in US$ Million by the following Product Segments: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Others.

The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of the World.

Annual estimates and forecasts are provided for each region for the period 2007 through 2015.

Also, a six-year historic analysis is provided for these markets.

The report profiles 61 companies including many key and niche players such as 3M Drug Delivery Systems Division, Akela Pharma Inc., Alkermes, Inc., Aradigm Corporation, AstraZeneca Plc, Baxter International Inc., Chiesi Farmaceutici SpA, Consort Medical Plc, Dey Pharma L.P., GlaxoSmithKline Plc, Graceway Pharmaceuticals, LLC, NovartiS AG, Oriel Therapeutics, Inc., Sepracor, Inc., SkyePharma Plc, Valois S.A.S, and Vectura Group Plc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Metered Dose Inhalers (MDIs)
Dry Powder Inhalers (DPIs)
Others
Nebulizers

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Drug Delivery Technologies: A Primer

Table 1. Worldwide Drug Delivery Market (2007): Percentage Share Breakdown of Revenue by Technology Segment (includes corresponding Graph/Chart)

Drug Delivery Technologies Turns Critically Important to Pharma Majors
The Need for Novel Drug Delivery Technologies From A Financial Standpoint
Pulmonary Drug Delivery: A Preferred, Non-Invasive Drug Administration Route
Market Fundamentals: A Current Review
Respiratory Disorders: A Large & Mature Therapeutic Category
Widely Prescribed Inhalation Drugs for Asthma & COPD
Inhaler Devices: An Integral Part of Pulmonary Drug Delivery
Pulmonary Delivery of Systemic Drugs: A Future Growth Area
Delivering Macromolecules Through the Lungs: A Current Focus Area
Innovations in Inhalation Aerosols
Current Drugs in Pipeline: A Review
Inhaled Drugs in Pipeline as of the Year 2008 & 2009
Noteworthy Trends & Issues
Nanotechnology Makes its Presence Felt in Inhaled Drugs
Innovation in Inhaler Devices: A Key Differentiating Factor
Innovation is the Name of the Game in the Nebulizer Segment
Nebulizers for Pediatric Care: Need of the Hour
CFC Propellants Give Way to HFA
Chinks in MDI’s Armor Work in Favor of DPI Market
Potential Challenges for DPI Market
Combination Therapy: An Effective Strategy in Optimum Disease Management

2.PRODUCT OVERVIEW

Definition of Pulmonary Drug Delivery System
Benefits of Pulmonary Drug Delivery Systems
Therapeutic Benefits
Titration by Therapy
Titration by Patient
Dose Reproducibility
High Bioavailability
Other Key Advantages
Pulmonary Drug Delivery Devices
An Overview of Key Features of Popular Inhalation Devices
Inhalers
Metered Dose Inhalers (MDIs)
Working Principle of an MDI
CFC-Propellant based MDIs
Ban on CFCs
Use of Spacers in MDIs
Benefits of Spacers
Pros & Cons
Advantages
Unique Benefits of pMDIs
Limitations
Issues
MDIs & Future
Dry Powder Inhalers (DPIs)
Inspiratory Flow Rate in DPIs
Working Principle of DPIs
Deaggregation in Dry Powder Inhalers (DPIs)
Types of DPIs
Passive DPI
Active DPI
Single-dose DPIs
Multi-dose DPIs
Other Types
Benefits of DPIs
Limitations
Issues
In a nutshell
Comparison with MDIs
Nebulizers
Working Principle of a Nebulizer
Use of UDMs in Nebulizers
Types of Nebulizers
Ultrasonic Nebulizers
Gray Areas
Benefits
Limitations
Pneumatic Nebulizers
Breath-Actuated Nebulizers
Continuous Nebulization
Active Venturi Nebulizers
New Designs for Improved Nebulizer Performance
Limitations of Nebulizers
Factors Influencing Clinical Effectiveness of Inhalation Device
Device Factors
Patient Factors
Drug Factors

3.AN OVERVIEW OF PULMONARY CONDITIONS AND THERAPIES

The Respiratory System
Pulmonary Drug Delivery – An Overview
Asthma and COPD – Major Respiratory Disease Conditions
Asthma: Primary Respiratory Syndrome
Trigger Factors
Magnitude of Disease
Chronic Obstructive Pulmonary Disease
Magnitude of Disease
Treatment of Asthma and COPD
Methods of Drug Delivery through Pulmonary Route
Aerosols Systems
Intratracheal Inhalation
Insufflation
Pulmonary Delivery Approaches
Controlled Release
Drug Medications for Treating Asthma and COPD
Bronchodilators (Acute Reliever Drugs)
Categories of Bronchodilators
Short acting beta-agonists
Long acting beta-agonists
Anti-cholinergics
Methylxanthines
Combination Bronchodilators
Available Inhaled Locally Acting Drugs
Anti-Inflammatory Medication (Controllers or Preventers)
Corticosteroids
Inhaled Corticosteroids in Asthma
Inhaled Corticosteroids in COPD
Anti-Leukotrienes
Innovative Therapeutic Approaches
Combination Therapeutics

4.PRODUCT INNOVATIONS/INTRODUCTIONS

Pearl Therapeutics Announces Phase II Trials of Glycopyrrolate Inhalation Aerosol in COPD
PARI Receives Patent for Vortex Holding Chamber
Schering-Plough Obtains Approval for Asmanex in Japan
SkyePharma Inc Receives FDA Communication on Flutiform
Almirall Announces Positive Results of Phase III Eklira
MicroDose Therapeutx Initiates Phase 1 Study with Inhaled Atropine
PARI Pharma Announces Successful Phase Ib Results for Inhaled L-CsA
PARI Respiratory Launches PEP S

3M DRUG DELIVERY SYSTEMS ROLLS OUT 3M CONIX DPI, 3M TAPER DPI

Akela Pharma Achieves Third Milestone in Fentanyl TAIFUN® Phase III Study
Vectura Group Announces Phase III Trials for NVA237, QVA149
Novartis Gets EU Approval for Onbrez® Breezhaler®
Novartis Gets Complete Response Letter for QAB149, from US FDA
Novartis Obtains EU Approval for Xolair® for Treating Severe Asthma in Children Under 11 Years
AstraZeneca Gets FDA Complete Response Letter for Symbicort in Paediatric Patients
AstraZeneca Gets FDA Approval for Symbicort in COPD

3M DRUG DELIVERY SYSTEMS UNVEILS 3M FACE SEAL VALVE, 3M PLASMA COATING TECHNOLOGY

Nanotechnology Victoria, Monash University Develops SAW Generated Mechanism
RTS Life Science Rolls Out Automated Inhaler Testing Solution
Eli Lilly &Co and Alkermes Abandon Inhaled Insulin Development Deal
Novo-Nordisk Drops Development Plan of Inhaled Insulin
Concomitant Use of Tiotropium, Nebulized Formoterol Fumarate to Relieve COPD Symptoms
Advair Gets FDA Nod for Advair 250/50

5.RECENT INDUSTRY ACTIVITY

Dainippon Sumitomo Concludes Acquisition of Sepracor
MicroDose Therapeutx Acquires ViroPharma Investigational Compounds
Sepracor Grants Non-Exclusive License for XOPENEX® to Teva and Barr
Skyepharma, Novartis Terminate Formoterol Certihaler Deal
Tidal Air to Sell Matrix Aerosol Delivery System
Battelle Memorial Institute Purchases Assets of Ventaira Pharmaceuticals Inc
Aptar Pharma to Roll Out Pulmonary & Nasal Devices In India

3M DRUG DELIVERY SYSTEMS UNVEILS NEW SINGAPOREAN FACILITY

Forest Laboratories, Almirall, Extend Collaboration for LAS100977
MicroDose Therapeutx, Merck Expand Collaboration Deal
AstraZeneca Sells API Facility to Minakem
ALR Technologies, Pari Enter Into Agreement
Akela Adds Amendment Into Fentanyl TAIFUN® License Deal with Teikoku Seiyaku
Novartis, Schering-Plough Revise Collaboration Terms
Astellas, AstraZeneca Ink Co-Promotion Agreement for Symbicort Turbuhaler
Iroko Cardio Inks Distribution Agreement with Chiesi Farmaceutici
Novartis Completes Acquisition of Nektar’s Pulmonary Business

3M, CAMBRIDGE CONSULTANTS FORGE LICENSING DEAL FOR DPI TECHNOLOGY

Savara Relocates Headquarters to Texas
GSK to Take Over Genelabs Technologies Inc
Novo Nordisk Hand Over Inhaled Insulin Patents to Aradigm
Sepracor Enters Into Agreement with Arrow International
Royal Philips Electronics Acquires Medel, Melhk
Aerogen Concludes Management Buyout from Nektar
Valois Pharma Bags Multi Million Contract

6.FOCUS ON SELECT PLAYERS

3M DRUG DELIVERY SYSTEMS DIVISION (USA)

Akela Pharma Inc (Canada)
Alkermes, Inc. (USA)
Aradigm Corporation (USA)
AstraZeneca Plc (UK)
Baxter International Inc. (USA)
Chiesi Farmaceutici SpA (Italy)
Consort Medical Plc (UK)
Dey Pharma L.P. (USA)
GlaxoSmithKline Plc (UK)
Graceway Pharmaceuticals, LLC (USA)
NovartiS AG (Switzerland)
Oriel Therapeutics, Inc. (USA)
Sepracor, Inc. (USA)
SkyePharma Plc (UK)
Valois S.A.S. (France)
Vectura Group Plc (UK)

7.GLOBAL MARKET PERSPECTIVE

Table 2. World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 3. World Historic Review for Pulmonary Drug Delivery Technologies by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 4. World 13-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart)

By Product Segments

Table 5. World Recent Past, Current and Future Analysis for Metered Dosage Inhalers (MDIs) by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 6. World Historic Review for Metered Dosage Inhalers (MDIs) by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 7. World 13-Year Perspective for Metered Dosage Inhalers (MDIs) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart)
Table 8. World Recent Past, Current and Future Analysis for Dry Powder Inhalers (DPIs) by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015(includes corresponding Graph/Chart)
Table 9. World Historic Review for Dry Powder Inhalers (DPIs) by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 10. World 13-Year Perspective for Dry Powder Inhalers (DPIs) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart)
Table 11. World Recent Past, Current and Future Analysis for Other Pulmonary Drug Delivery Technologies by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 12. World Historic Review for Other Pulmonary Drug Delivery Technologies by Geographic Region – US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 13. World 13-Year Perspective for Other Pulmonary Drug Delivery Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin America and Rest of the World Markets for Years 2003, 2009, and 2015 (includes corresponding Graph/Chart)

III. MARKET

1.THE UNITED STATES

A. MARKET ANALYSIS

Outlook
Current Market Scenario
Major Growth Areas/Indicators
Respiratory Diseases
Cancer
Cystic Fibrosis
HFA Albuterol Eats into CFC Inhalers Market

Table 14. US Albuterol Inhalers Market in Aerosol Beta Agonists Category (2006 & 2007): Percentage Share Breakdown of Revenue by Product Type (includes corresponding Graph/Chart)

New & Popular DPIs in the US
Nebulizers: Displaying Promising Growth

Table 15. US Nebulizers Market (2008): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart)

Role of FDA
Key Market Share Findings

Table 16. US Bronchodilators Market (2006): Percentage Share Breakdown of Revenues by Key Players (includes corresponding Graph/Chart)
Table 17. US Anti-Inflammatory Market (2006): Percentage Share Breakdown of Revenues by Key Players (includes corresponding Graph/Chart)
Table 18. US Bronchodilators Market (2009): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart)
Table 19. US Anti-Inflammatory Market (2006): Percentage Share Breakdown of Revenues by Segment (includes corresponding Graph/Chart)

Product Launches/Developments
Strategic Corporate Developments
Select Players

B. MARKET ANALYTICS

Table 20. US Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 21. US Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 22. US 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

2.CANADA

A. MARKET ANALYSIS

Outlook
Product Launch
Strategic Corporate Developments
Akela Pharma Inc – A Key Canadian Player

B. MARKET ANALYTICS

Table 23. Canadian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 24. Canadian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 25. Canadian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

3.JAPAN

A. MARKET ANALYSIS

Outlook
Product Launch
Strategic Corporate Development

B. MARKET ANALYTICS

Table 26. Japanese Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 27. Japanese Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 28. Japanese 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4.EUROPE

A. MARKET ANALYSIS

Outlook
Growth Drivers

Table 29. European Drug Delivery Market: Number of Deals Between Pharmaceutical/ Biotechnology Companies and Drug Delivery Companies for 2004 & 2007

Focus of R&D Shifts to Diabetes Treatment

Table 30. Research Activity Distribution in the European Pulmonary Drug Delivery Market (2007): Percentage Share Breakdown of Activity by Therapeutic Area (includes corresponding Graph/Chart)

European Pulmonary Drug Delivery Market: Drugs In Clinical Pipeline As of 2007
DPIs in Europe
Product Launches/Developments
Strategic Corporate Developments
Novartis Ag (Switzerland) – A Key European Player

B. MARKET ANALYTICS

Table 31. European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 32. European Historic Review for Pulmonary Drug Delivery Technologies by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 33. European 13-Year Perspective for Pulmonary Drug Delivery Technologies by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2009 and 2015 (includes corresponding Graph/Chart)
Table 34. European Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 35. European Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 36. European 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4A.FRANCE

A. MARKET ANALYSIS

Outlook
Strategic Corporate Development
Valois S.A.S. – A Key Player

B. MARKET ANALYTICS

Table 37. French Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 38. French Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 39. French 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4B.GERMANY

Market Analysis

Table 40. German Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 41. German Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 42. German 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4C.ITALY

A. MARKET ANALYSIS

Outlook
Chiesi Farmaceutici SpA – A Key Player

B. MARKET ANALYTICS

Table 43. Italian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 44. Italian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 45. Italian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4D.THE UNITED KINGDOM

A. MARKET ANALYSIS

Outlook
Market Overview
Areas of Growth
Progress in Drug Delivery
Product Launches/Developments
Strategic Corporate Developments
Select Players

B. MARKET ANALYTICS

Table 46. UK Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 47. UK Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 48. UK 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4E.SPAIN

Market Analysis

Table 49. Spanish Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 50. Spanish Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 51. Spanish 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4F.RUSSIA

Market Analysis

Table 52. Russian Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 53. Russian Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 54. Russian 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

4G.REST OF EUROPE

Market Analysis

Table 55. Rest of Europe Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 56. Rest of Europe Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 57. Rest of Europe 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

5.ASIA-PACIFIC

A. MARKET ANALYSIS

Outlook
Regional Snapshot
India
Nebulizers Market in India: A Quick Primer
Dry Powder Inhalers for Children
Product Launch
Strategic Corporate Developments

B. MARKET ANALYTICS

Table 58. Asia-Pacific Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 59. Asia-Pacific Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 60. Asia-Pacific 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

6.LATIN AMERICA

Market Analysis

Table 61. Latin American Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 62. Latin American Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 63. Latin American 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

7.REST OF WORLD

Market Analysis

Table 64. Rest of World Recent Past, Current and Future Analysis for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 65. Rest of World Historic Review for Pulmonary Drug Delivery Technologies by Product Segment – Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart)
Table 66. Rest of World 13-Year Perspective for Pulmonary Drug Delivery Technologies by Product Segment – Percentage Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 61 (including Divisions/Subsidiaries - 75)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Middle East
Skip to top


Ask Your Question

Pulmonary Drug Delivery Technologies: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: